The novel small-molecule antagonist of PAC1 receptor attenuates formalin-induced inflammatory pain behaviors in mice

J Pharmacol Sci. 2019 Feb;139(2):129-132. doi: 10.1016/j.jphs.2018.11.011. Epub 2018 Dec 1.

Abstract

We recently developed PA-8, a novel small-molecule antagonist of PACAP type 1 (PAC1) receptor. In the present study, we examined whether PA-8 was effective against formalin-induced inflammatory pain in mice. Both intrathecal and oral administration of PA-8 resulted in the dose-dependent attenuation of the second phase of formalin-induced nociceptive responses. PA-8 also inhibited c-fos upregulation in the ipsilateral dorsal horn of the spinal cord. The results suggested that PACAP-PAC1 receptor signaling system in the spinal cord were primarily involved in the transmission of inflammatory pain, and PA-8 could be useful for the development of novel analgesics for treating inflammatory pain.

Keywords: Inflammatory pain; PACAP type 1 (PAC1) receptor; Small-molecule antagonist.

MeSH terms

  • Analgesics / therapeutic use*
  • Animals
  • Anti-Inflammatory Agents / therapeutic use
  • Behavior, Animal / drug effects
  • Formaldehyde
  • Injections, Spinal
  • Male
  • Mice
  • Pain / drug therapy*
  • Pain / metabolism
  • Proto-Oncogene Proteins c-fos / metabolism
  • Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I / antagonists & inhibitors*
  • Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I / metabolism
  • Spinal Cord / drug effects
  • Spinal Cord / metabolism

Substances

  • Analgesics
  • Anti-Inflammatory Agents
  • Proto-Oncogene Proteins c-fos
  • Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I
  • Formaldehyde